Selective Pulmonary-artery Intervention to Reduce Acute Right-heart tEnsion-II

Launched by JUPITER ENDOVASCULAR · Aug 26, 2024

Keywords

ClinConnect Summary

The Selective Pulmonary-artery Intervention to Reduce Acute Right-heart tEnsion-II trial is studying a new device called the Vertex Pulmonary Embolectomy System, which is designed to help patients with acute pulmonary embolism (a blockage in the lungs' blood vessels). This study aims to determine how safe and effective this device is for treating patients who show symptoms of this serious condition, which can occur suddenly and may require urgent medical attention.

To be eligible to participate, individuals must be between 18 and 79 years old and have experienced symptoms of pulmonary embolism within the last two weeks. They will also need to have specific imaging test results showing a blockage in the main blood vessels of the lungs. Participants will be closely monitored throughout the study and must be willing to attend follow-up visits. It's important to note that this trial is currently recruiting, meaning that eligible patients can still join the study. If you or a loved one is considering participation, it’s a good opportunity to help advance treatment options for this serious condition.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• • 1. Age ≥ 18 years \< 80 years
• • 2. Acute onset of symptoms ≤ 14 days consistent with the presence of pulmonary embolism.
• • 3. CTA evidence (site determined) of proximal PE (filling defect in at least one main or interlobar pulmonary artery)
• • 4. RV/LV ratio of \> 0.9 on CTA as assessed by investigator (site determined).
• • 5. Systolic blood pressure ≥ 90 mmHg (initial SBP may be ≥ 80 mmHg if the pressure recovers to ≥ 90 mmHg with fluids)
• • 6. Subject or subject's legally authorized representative (LAR) is willing and able to provide written informed consent prior to receiving any non-standard of care Protocol-specific procedures
• • 7. Subject is willing and able to comply with all Protocol-required follow-up visits
• • Exclusion Criteria
• • 1. Thrombolytic use within 30 days of baseline CTA
• • 2. Pulmonary hypertension with peak pulmonary artery pressure \> 70 mmHg by right heart catheterization (site determined)
• • 3. Vasopressor requirement after fluids to keep pressure ≥ 90 mmHg
• • 4. Unstable heart rate \> 130 beats per minute prior to procedure
• • 5. FiO2 requirement \> 40% or \> 6 LPM to keep oxygen saturation \> 90%
• • 6. Hematocrit \< 28%
• • 7. Platelets \< 100,000/μL
• • 8. Serum baseline creatinine \> 1.8 mg/dL
• • 9. International normalized ratio (INR) \> 3
• • 10. Major trauma injury severity score (ISS) \> 15 within the past 14 days
• • 11. Presence of intracardiac lead in the right ventricle or right atrium placed \<180 days prior to the index procedure
• • 12. Cardiovascular or pulmonary surgery within last 30 days
• • 13. Actively progressing cancer requiring chemotherapy
• • 14. Known bleeding diathesis or coagulation disorder
• • 15. Left bundle branch block
• • 16. History of severe or chronic pulmonary arterial hypertension
• • 17. History of chronic left heart disease with left ventricular ejection fraction ≤ 30%
• • 18. History of decompensated heart failure
• • 19. Patients on extracorporeal membrane oxygenation (ECMO)
• • 20. History of underlying lung disease that is oxygen dependent
• • 21. History of chest irradiation
• • 22. History of heparin-induced thrombocytopenia (HIT)
• • 23. Contraindication to systemic or therapeutic doses of heparin or anticoagulants
• • 24. Known anaphylactic reaction to radiographic contrast agents that cannot be pretreated
• • 25. Imaging evidence or other evidence that suggests, in the opinion of the Investigator, the Subject is not appropriate for mechanical thrombectomy intervention
• • 26. Life expectancy of \< 365 days, as determined by Investigator
• • 27. Female who is pregnant or nursing
• • 28. Current participation in another investigational drug or device treatment study
• • 29. Inability to lay flat for procedure
• • 30. Known presence of right-to-left cardiac shunt
• • 31. History of Hemorrhagic or Ischemic Stroke, including Transient Ischemic Attack, within last 90 days
• • 32. Current or history of chronic thromboembolic pulmonary hypertension (CTEPH) or chronic thromboembolic disease (CTED) diagnosis